Frequency of CCR5-Δ32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population

International Journal of Molecular Medicine

Volumn 22, Issue 5, 2008, Pages 669-675

  Reiche, Edna Maria Vissoci ^a   Watanabe, Maria Angelica Ehara ^a   Bonametti, Ana Maria ^a   Morimoto, Helena Kaminami ^a   Morimoto, Arilson Akira ^a,b   Wiechmann, Susana Lílian ^a   Matsuo, Tiemi ^a   De Oliveira, Jaqueline Carvalho ^a   Reiche, Fernando Vissoci ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b Integrated Center of Infectious Diseases   (Brazil)

Author keywords

AIDS; CCR5 32 allele; Chemokine receptor; Genetic polymorphism; Human immunodeficiency virus type 1

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 DELTA32; DNA FRAGMENT; GENOMIC DNA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; ARTICLE; BASE PAIRING; BLOOD DONOR; BRAZIL; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENOTYPE; HEREDITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; WILD TYPE; CLINICAL TRIAL; FEMALE; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MALE; MULTICENTER STUDY; SERODIAGNOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALLELES; BLOOD DONORS; BRAZIL; FEMALE; GENE FREQUENCY; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, INNATE; MALE; RECEPTORS, CCR5; SEQUENCE DELETION;

EID: 59149085118     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000071     Document Type: Article

References (61)

1. Bates I, Fenton C, Gruber J, Lalloo D, Lara M, Squire SB, Theobald S, Thomson R and Tolhurst R: Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet 4: 267-277, 2004.
2. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP and Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362: 355-358, 1993.
3. Hogan C and Hammer S: Host determinants in HIV infection and disease: Part 1: cellular and humoral responses. Ann Intern Med 134: 761-776, 2001.
4. Hogan C and Hammer S: Host determinants in HIV infection and disease: Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 134: 978-996, 2001.
5. Evans DT and Desrosiers RC: Immune evasion strategies of the primate lentiviruses. Immunol Rev 183: 141-158, 2001.
6. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Bichbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R and O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273: 1856-1862, 1996.
7. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA and Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377, 1996.
8. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille CM, Muylderman G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G and Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-725, 1996.
9. Zimmerman P, Bucker-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, Cohen O, Rubbert A, Lam G, Vaccarezza M, Kennedy PE, Kumaraswami V, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB and Murphy PM: Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 3: 23-36, 1997.
10. Huang Y, Paxton WA, Wolinksy SM, Wolinsky SM, Neumann AU, Zhang L, He T, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD and Koup RA: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2: 1240-1243,1996.
11. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW and O'Brien SJ: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 277: 959-965, 1997.
12. Martin MP, Dean M, Smith MW, Winkler C, Gerard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S, Goedert JJ, O'Brien TR, Hilgartner MW, Vlahov D, O'Brien SJ and Carrington M: Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282: 1907-1911, 1998.
13. de Roda Husman AM, Koot M, Cornelissen M, Keet IPM, Brouwer M, Broersen SM, Bakker M, Roos MTL, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J and Schuitemaker H: Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 127: 882-890, 1997.
14. Meyer L, Magierowska M, Hubert J-B, Theodorou I, van Rij R, Prins M, de Roda Husman A-M, Coutimho R and Schuitemaker H: CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. AIDS 13: 624-626, 1999.
15. Ioannidis JP, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DG and Goedert JJ: Genetic effects on HIV disease progression. Nat Med 4: 536, 1998.
16. Ioannidis JPA, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie LG, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workamn C, Zagury J-F and O'Brien TR: Effects of CCR5 [Delta]32, CCR2-64I, and SDF-1 3'A alleles on HIV disease progression: an international metaanalysis of individual-patient data. Ann Intern Med 135: 782-795, 2001.
17. Cohen OJ, Kinter A and Fauci AS: Host factors in the pathogenesis of HIV disease. Immunol Rev 159: 31-48, 1997.
18. Eugen-Olsen J, Iversen AKN, Garred P, Koppelhus U, Pedersen C, Benfield TL, Sorensen AM, Ktzenstein T, Dickmeiss E, Gerstoft J, Skinhoj P, Svejgaard A, Nielsen JO and Hofmann B: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free of HIV-seropositive individuals. AIDS 11: 305-310, 1997.
19. Apostolakis S, Baritaki S, Krambovitis E and Spandidos DA: Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population. J Clin Virol 34: 310-314, 2005.
20. Martinson JJ, Chapman NH, Rees DC, Liu YT and Clegg JB: Global distribution of the CCR5 gene 32 base-pair deletion. Nat Genet 16: 100-103, 1995.
21. Libert F, Cochaux P, Beckman G, Samson M, Aksenova M, Cao A, Czeizel A, Claustres M, de la Rúa C, Ferrari M, Ferrec C, Glover G, Grinde B, Güran S, Kucinskas V, Lavinha J, Mercier B, Ogur G, Peltonen L, Rosatelli C, Schwartz M, Spitsyn V, Timar L, Beckman L, Parmentier M and Vassart G: The delta CCR5 mutation conferring protection against HIV-1 in Caucasian population has a single and recent origin in Northeastern Europe. Hum Mol Genet 7: 399-406, 1998.
22. Lu Y, Nerurkar VR, Dashwood WM, Woodward CL, Ablan S, Shikuman CM, Grandinetti A, Chang H, Nguyen HT, Wu Z, Yamamura Y, Boto WO, Merriwether A, Kurata T, Detels R and Yanagihaa R: Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders. Int J Infect Dis 3: 186-191, 1999.
23. Nookhai S, Ruxrungtham K, Phanuphak P and Oelrichs R: Prevalence of CCR2-64I, SDF1-3′A and CCR5-Δ32 alleles in healthy Thais. Eur J Immunogenet 27: 153-157, 2000.
24. Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM and Ghaderi A: The frequency of CCR5-Δ32 and CCR2-64I in southern Iranian normal population. Immunol Lett 96: 277-281, 2005.
25. Salem A-H and Batzer MA: Distribution of the HIV resistance CCR5-Δ32 allele among Egyptians and Syrians. Mutat Res 616: 175-180, 2007.
26. Diaz FJ, Vega JA, Patino PJ, Bedoya G, Nagles J, Villegas C, Vesga R and Rugeles MT: Frequency of CCR5 delta-32 mutation in human immunodeficiency virus (HIV)-seropositive and HIV-exposed seronegative individuals and in general population of Medelin, Colombia. Mem Inst Oswaldo Cruz 95: 237-242, 2000.
27. Passos GA Jr and Picanco VP: Frequency of the delta CCR5 deletion allele in the urban Brazilian population. Immunol Lett 61: 205-207, 1998.
28. Leboute APM, Carvalho MWO and Simões AL: Absence of the delta CCR5 mutation in indigenous populations of the Brazilian Amazon. Hum Genet 105: 442-443, 1999.
29. Grimaldi R, Shindo N, Acosta AX, Dourado I, Brites C, Carvalho O de, Brito I, Bou-Habib DC and Galvão-Castro B: Prevalence of the CCR5-Δ32 mutation in Brazilian populations and cell susceptibility to HIV-1. Hum Genet 111: 102-104, 2002.
30. Vargas AE, Marrero AR, Salzano FM, Bortolini MC and Chies JAB: Frequency of CCR5-Δ32 in Brazilian populations. Braz J Med Biol Res 39: 321-325, 2006.
31. UNAIDS - Joint United Nations Programme on HIV/AIDS. AIDS epidemic update: special report on HIV/AIDS: December 2007.
32. a. semanas epidemiológicas- January-June, 2006. Boletim Epidemiológico AIDS 1: 3-49, 2006. (in Portuguese)
33. Reiche EMV, Bonametti AM, Watanabe MAE, Morimoto HK, Morimoto AA, Wiechmann SL, Breganó JW, Matsuo T and Reiche FV: Socio-demographic and epidemiological characteristics associated with human immunodeficiency virus type 1 (HIV-1) infection in HIV-1-exposed but uninfected individuals, and in HIV-1-infected patients from a southern Brazilian population. Rev Inst Med Trop Sao Paulo 47: 239-246, 2005.
34. Reiche EMV, Watanabe MAE, Bonametti AM, Morimoto HK, Morimoto AA, Wiechamnn SL, Matsuo T, Miranda HC, Reiche FV and Oliveira KB: Stromal cell-derived factor 1 (SDF1) genetic polymorphism in a sample of healthy individuals, seronegative individuals exposed to human immunodeficiency virus type 1 (HIV-1) and patients infected with HIV-1 from the Brazilian population. Int J Immunogenet 33: 127-133, 2006.
35. Reiche EMV, Watanabe MAE, Bonametti AM, Morimoto HK, Morimoto AA, Wiechamnn SL, Breganó JW, Matsuo T, Reiche FV, Miranda HC, Oliveira KB, Vogler IH and Siscar AR: The effect of stromal cell-derived factor 1 (SDF1/CXCL12) genetic polymorphism on HIV-1 disease progression. Int J Mol Med 18: 785-793, 2006.
36. CDC. Center for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women. Morb Mortal Wkly Rep 50: 8-9, 2001.
37. Brazil. Ministry of Health. National Coordination of Sexually Transmitted Diseases (STD) and AIDS. Recomendações para Terapia anti-retroviral em adultos e adolescentes infectados pelo HIV 2002/2003, Brasília, 2002. URL: http://www.aidsw.gov.br Captured in 27/12/2002, 2002. (in Portuguese)
38. Brazil. Ministry of Health. National Coordination of Sexually Transmitted Diseases (STD) and AIDS. Revisão da Definição Nacional de Caso de AIDS em indivíduos com 13 anos ou mais, para fins de vigilância epidemiológica. Brasília: Ministry of Health, 1998. (in Portuguese)
39. Brazil. Ministry of Health. Agência Nacional de Vigilância Sanitária. Portaria no. 488 de 17 de junho de 1998, 1998. (in Portuguese)
40. Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16: 1215-1219, 1988.
41. Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH, Dicker RC, Sullivan K, Fagan RF and Arner TG: Epi Info, Version 6.0: World-processing database, and statistics program for Public Health on IBM-compatible microcomputers. Centers for Disease Control and Prevention, Atlanta, Georgia, 1995.
42. SAS Institute Inc. SAS/STAT User's Guide, Version 6, Fourth Edition, Cary, NC: SAS Institute Inc., 1989.
43. Trecarichi EM, Tumbarello M, de Gaetano Donati K, Tamburrini E, Cauda R, Brahe C and Tiziano FD: Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Res Ther 3: 22, 2006.
44. Alves-Silva J, Santos MS, Guimarães PEM, Ferreir ACS, Bandelt H-J, Pena SDJ and Prado VF: The ancestry of Brazilian mtDNA lineages. Am J Hum Genet 67: 444-461, 2000.
45. Mikawa AY, Tagliavini SA and Costa PI: CCR5 genotype and plasma β-chemokine concentration of Brazilian HIV-infected individuals. Braz J Med Biol Res 35: 1333-1337, 2002.
46. Rugeles MT, Solano F, Díaz FJ, Bedoya VI and Patiño PJ: Molecular characterization of the CCR 5 gene in seronegative individuals exposed to human immunodeficiency virus (HIV). J Clin Virol 23: 161-169, 2002.
47. Suresh P, Wanchu A, Sachdeva RK and Bhatnagar A: Gene polymorphism in CCR5, CCR2, CXCR3, SDF1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India. J Clin Immunol 26: 476-484, 2006.
48. Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK and Watanabe MAE: Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 14: 1325-1334, 2007.
49. Lama J and Planelles V: Host Factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology 4: 52, 2007.
50. Haynes BF, Pantaleo G and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 271: 324-328, 1996.
51. Costello C, Tang J, Rivers C, Karita E, Meiaen-Derr J, Allen S and Kaslow RA: HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS 13: 1990-1991, 1999.
52. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K and O'Brien SJ: HLA and HIV-1: heterozygosity advantage and B*35-Cw*04 disadvantage. Science 283: 1748-1752, 1999.
53. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho H-N, Nishanian PG, Berzofsky JA and Shearer GM: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 165: 1012-1019, 1992.
54. Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F and Oksenhendler E: Human immunodeficiency virus (HIV) nef-specific cytotoxic T lympohocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest 93: 1293-1297, 1994.
55. Plummer FA, Ball TB, Kimani J and Fowke KR: Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop? Immunol Lett 66: 27-34, 1999.
56. Fowke KR, Nagelkerke NJD, Kimani J, Simonses JN, Anzala AO, Bwayo JJ, MacDonald KS, Ngugi EN and Plummer FA: Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348: 1347-5131, 1996.
57. Rowland-Jones SL, Nixon DF, Aldhous MC, Aldhous MC, Gotch F, Atiyoshi K, Hallam N, Kroll JS, Froebel K and McMichael A: HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341: 860-861, 1993.
58. Bernard NF, Yannakis CM, Lee JS and Tsoukas CM: Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. J Infect Dis 179: 538-547, 1999.
59. Goh WC, Markee J, Akridge RE, Meldorf M, Musey L, Karchmer T, Krone M, Collier A, Corey L, Emerman M and McElrath MJ: Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 179: 548-557, 1999.
60. + T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 181: 927-932, 2000.
61. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE and Sheppard HW: The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 3: 1160-1162, 1997.